PSCK9
On GLOBE Final Rule
The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
Petauri™ Further Expands Global Pricing and Market Access Capabilities With Key Leadership Hires
Rapidly growing pharmaceutical services platform announces the addition of accomplished executives to the organization’s global pricing and market access team.
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...
Your essential guide to the World EPA Congress 2025: Top sessions and pre-reading
The World EPA organisers have curated an exceptional programme featuring thought-provoking presentations and dynamic panel sessions led by industry leaders driving market access strategy and practice. Following the opening keynote...
What is willingness to pay? – Comparing price testing methodologies
Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...
Mtech Access are exhibiting at ISPOR in the US
After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...
Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol
Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment
The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...